Ascimib is indicated for the treatment of adult patients with: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Ph+ CML in CP with the T315I mutation.
Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket. In studies conducted in vitro or in animal models of CML, asciminib showed activity against wild-type BCR-ABL1 and several mutant forms of the kinase, including the T315I mutation. Asciminib steady-state exposure (AUC and Cmax) increase slightly more than dose proportional across the dose range of 10 to 200 mg (0.25 to 5 times the recommended 80 mg daily dosage) administered once or twice daily. Pharmacokinetic parameters are presented as geometric mean (CV%) unless otherwise stated.
Recommended Dosage in Patients with Ph+ CML-CP, Previously Treated with Two or More TKIs : The recommended dose of Asciminib is 80 mg taken orally once daily at approximately the same time each day or 40 mg twice daily at approximately 12-hour intervals. The recommended dose of Asciminib is taken orally without food. Avoid food consumption for at least 2 hours before and 1 hour after taking Asciminib. Continue treatment with Asciminib as long as clinical benefit is observed or until unacceptable toxicity occurs. Recommended Dosage in Patients with Ph+ CML-CP with the T315I Mutation : The recommended dose of Asciminib is 200 mg taken orally twice daily at approximately 12-hour intervals. The recommended dose of Asciminib is taken orally without food. Avoid food consumption for at least 2 hours before and 1 hour after taking Asciminib. Missed Dose : Once Daily Dosage Regimen: If a Asciminib dose is missed by more than approximately 12 hours, skip the dose and take the next dose as scheduled. Twice Daily Dosage Regimens: If a Asciminib dose is missed by more than approximately 6 hours, skip the dose and take the next dose as scheduled. Dosage Modifications : Recommended Dosage Reductions for Asciminib for Adverse Reactions Dosage for Patients with CP-CML, Previously Treated with Two or More TKIs is 40 mg once daily or, 20 mg twice daily. Permanently discontinue Asciminib in patients unable to tolerate 40 mg once daily or, 20 mg twice daily. Dosage for Patients with Ph+ CML-CP with the T315I Mutation is 160 mg twice daily. Permanently discontinue Asciminib in patients unable to tolerate 160 mg twice daily.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
The following clinically significant adverse reactions can occur with Ascimib and are discussed in greater detail in other sections of the labeling: Myelosuppression Pancreatic Toxicity Hypertension Hypersensitivity Cardiovascular Toxicity
Strong CYP3A4 Inhibitors : Ascimib is a CYP3A4 substrate. Concomitant use of Ascimib with a strong CYP3A4 inhibitor increases both the Ascimib Cmax and AUC, which may increase the risk of adverse reactions. Closely monitor for adverse reactions in patients treated with Ascimib at 200 mg twice daily with concomitant use of strong CYP3A4 inhibitors. Itraconazole Oral Solution Containing Hydroxypropyl-β-cyclodextrin : Concomitant use of Ascimib with itraconazole oral solution containing hydroxypropyl-β-cyclodextrin decreases Ascimib Cmax and AUC, which may reduce Ascimib efficacy. Avoid coadministration of Ascimib at all recommended doses with itraconazole oral solution containing hydroxypropyl-βcyclodextrin.
Myelosuppression Thrombocytopenia, neutropenia, and anemia have occurred in patients receiving Ascimib. Thrombocytopenia occurred in 98 of 356 (28%) patients receiving Ascimib, with Grade 3 or 4 thrombocytopenia reported in 24 (7%) and 42 (12%) of patients, respectively. Among the patients with Grade 3 or 4 thrombocytopenia, median time to first occurrence of events was 6 weeks (range, 0.1 to 64 weeks). Of the 98 patients with thrombocytopenia, 7 (2%) patients permanently discontinued Ascimib while Ascimib was temporarily withheld in 45 (13%) patients due to the adverse reaction. Pancreatic Toxicity : Pancreatitis occurred in 9 of 356 (2.5%) patients receiving Ascimib, with Grade 3 pancreatitis occurring in 4 (1.1%) patients. All cases of pancreatitis occurred in the Phase I study (X2101). Of the 9 patients with pancreatitis, two (0.6%) patients permanently discontinued Ascimib, while Ascimib was temporarily withheld in 4 (1.1%) patients due to the adverse reaction. Asymptomatic elevation of serum lipase and amylase occurred in 76 of 356 (21%) patients receiving Ascimib, with Grade 3 and Grade 4 pancreatic enzyme elevations occurring in 36 (10%) and 8 (2.2%) patients, respectively. Of the 76 patients with pancreatic enzymes elevated, Ascimib was permanently discontinued in 7 (2%) patients due to the adverse reaction. Hypertension : Hypertension occurred in 66 of 356 (19%) patients receiving Ascimib, with Grade 3 or 4 hypertension reported in 31 (9%) and 1 (0.3%) patients, respectively. Among the patients with Grade 3 or 4 hypertension, median time to first occurrence was 14 weeks (range, 0.1 to 156 weeks). Of the 66 patients with hypertension, Ascimib was temporarily withheld in 3 (0.8%) patients due to the adverse reaction. Hypersensitivity : Hypersensitivity occurred in 113 of 356 (32%) patients receiving Ascimib, with Grade 3 or 4 hypersensitivity reported in 6 (1.7%) patients. Reactions included rash, edema, and bronchospasm. Monitor patients for signs and symptoms of hypersensitivity and initiate appropriate treatment as clinically indicated; for Grade 3 or higher hypersensitivity, temporarily withhold, reduce dose, or permanently discontinue depending Ascimib depending on persistence of hypersensitivity. Cardiovascular Toxicity : Cardiovascular toxicity (including ischemic cardiac and CNS conditions, arterial thrombotic and embolic conditions) and cardiac failure occurred in 46 (13%) and in 8 (2.2%) of 356 patients receiving Ascimib, respectively. Grade 3 cardiovascular toxicity was reported in 12 (3.4%) patients, while grade 3 cardiac failure was observed in 4 (1.1%) patients. Grade 4 cardiovascular toxicity occurred in 2 (0.6%) patients, with fatalities occurring in 3 (0.8%) patients. Permanent discontinuation of Ascimib occurred in 3 (0.8%) patients due to cardiovascular toxicity and in 1 (0.3%) patient due to cardiac failure, respectively. Cardiovascular toxicity occurred in patients with pre-existing cardiovascular conditions or risk factors, and/or prior exposure to multiple TKIs. Embryo-Fetal Toxicity : Based on findings from animal studies and its mechanism of action, Ascimib can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of Ascimib to pregnant rats and rabbits during the period organogenesis caused adverse developmental outcomes including embryo-fetal mortality and malformations at maternal exposures (AUC) equivalent to or less than those in patients at the recommended doses. Advise pregnant women and females of reproductive potential of the potential risk to a fetus if Ascimib is used during pregnancy or if the patient becomes pregnant while taking Ascimib. Verify the pregnancy status of females of reproductive potential prior to starting treatment with Ascimib. Females of reproductive potential should use effective contraception during treatment with Ascimib and for 1 week after the last dose.